3,6-DIBROMO-ALPHA-(1-PIPERAZINYLMETHYL)-9H-CARBAZOLE-9-ETHANOL DIHYDROCHLORIDE Property

Boiling point:

388.1±42.0 °C(Predicted)

Density 

1.71±0.1 g/cm3(Predicted)

storage temp. 

Keep in dark place,Inert atmosphere,Room temperature

solubility 

≥28.2 mg/mL in DMSO with ultrasonic; insoluble in EtOH; insoluble in H2O

form 

solid

pka

14.48±0.20(Predicted)

color 

White

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H315Causes skin irritation

H319Causes serious eye irritation

H335May cause respiratory irritation

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

3,6-DIBROMO-ALPHA-(1-PIPERAZINYLMETHYL)-9H-CARBAZOLE-9-ETHANOL DIHYDROCHLORIDE Chemical Properties,Usage,Production

Uses

Bax channel blocker is a potent inhibitor of Bax-mediated mitochondrial cytochrome c release.

Biological Activity

Potent inhibitor of Bax-mediated mitochondrial cytochrome c release (IC 50 = 0.52 μ M). Suggested to inhibit Bax channel formation/activity.

in vitro

bax channel blocker, a 3,6-dibromocarbazole derivative, was observed to inhibit cytochrome c releasing from mitochondria by bax channel modulation. the monohydroxy analogue bax channel blocker remained the unprecedented inhibition of bax-induced cytochrome c release at 10 μm. the ic50 value of bax channel blocker was determined to be 0.52 μm, indicating that bax channel blocker was a bax channel inhibitor as hypothesized. moreover, in the liposome assay, bax channel blocker showing significant inhibition (>65%) of cytochrome c release at 10 μm also demonstrated sub-micromolar ic50 value [1].

IC 50

0.52 μm in bax assay

References

[1] bombrun a,gerber p,casi g,terradillos o,antonsson b,halazy s. 3,6-dibromocarbazole piperazine derivatives of 2-propanol as first inhibitors of cytochrome c release via bax channel modulation. j med chem.2003 oct 9;46(21):4365-8.